Clinical trial · Interventional
1 Week Versus 6 Weeks of Levetiracetam in Surgical Brain Tumor Patients
A Shortened Antiepileptic Drug (AED) Course in Surgical Brain Tumor Patients: A Randomized Trial
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to see if there are any differences in patient reported neurotoxicity between patients who receive Levetiracetam tablets for one week after surgery to remove a brain tumor versus those who receive Levetiracetam tablets for six weeks after surgery. Specifically, we will see if one group has less side effects than the other, and whether or not one group has more seizures than the other.
Conditions
Conditions (6)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain Cancer | Malignant Brain Neoplasm | ALIAS | 0.90 |
| Brain Neoplasms | Brain Neoplasm | ONTOLOGY_EXACT | 0.90 |
| Brain Tumors | Brain Neoplasm | ALIAS | 0.90 |
| Cancer of Brain | Malignant Brain Neoplasm | ALIAS | 0.90 |
| Cancer of the Brain | Malignant Brain Neoplasm | ALIAS | 0.90 |
| Seizure | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Levetiracetam | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- 1 Week Levetiracetam
- description
- Levetiracetam taken by mouth at a daily dose of 1000 mg for one week.
- interventionNames
- Drug: Levetiracetam
- type
- ACTIVE_COMPARATOR
- label
- 6 Week Levetiracetam
- description
- Levetiracetam taken by mouth at a daily dose of 1000 mg for six weeks.
- interventionNames
- Drug: Levetiracetam
Primary outcomes (1)
- measure
- Change in Neurotoxicity Scale Scores
- timeFrame
- Baseline to 6 weeks
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adult (\>18 years of age and older) patients who have or will have undergone surgical resection or biopsy of a supratentorial brain tumor and are able to consent for themselves. * Able to be randomized prior to or up to 48 hours after surgery. Exclusion Criteria: * No known history of seizure activity. * Pregnant or breastfeeding. * Renal dysfunction (CrCl \< 30ml/min). * Beck's Depression Inventory (BDI) ≥14 * Allergy to levetiracetam.
References
Publications (0)
Data not yet available